Efficacy of Sildenafil in Patients with Severe COVID-19 and Pulmonary Arterial Hypertension

Pulmonary arterial hypertension (PAH) is common in severe coronavirus disease 2019 (COVID-19) and worsens the prognosis. Sildenafil, a phosphodiesterase-5 inhibitor, is approved for PAH treatment but little is known about its efficacy in cases of severe COVID-19 with PAH. This study aimed to investi...

Descripción completa

Detalles Bibliográficos
Autores principales: Oliynyk, Oleksandr Valentynovych, Rorat, Marta, Strepetova, Olena Vadymivna, Dubrov, Serhij Oleksandrovych, Guryanov, Vitaliy Grygorovych, Oliynyk, Yanina Volodymyrivna, Kulivets, Oleksii Serhijovych, Ślifirczyk, Anna, Barg, Wojciech
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10223625/
https://www.ncbi.nlm.nih.gov/pubmed/37243243
http://dx.doi.org/10.3390/v15051157

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10223625/
https://www.ncbi.nlm.nih.gov/pubmed/37243243
http://dx.doi.org/10.3390/v15051157

Ejemplares similares